Sort   by:  
 Page size 
MetabolomicsMesenchymal stromal cells secretome restores bioenergetic and redox homeostasis in human proximal tubule cells after ischemic injury

BACKGROUND: Ischemia/reperfusion injury (IRI) is the leading cause of acute kidney injury (AKI). The current standard of care focuses on supporting kidney function, stating the need for more efficient and targeted therapies to enhance repair. Mesenchymal Stromal Cells (MSCs) and ...

2023-10-16 | MTBLS6279 | MetaboLights
ProteomicsEffect of therapy-induced secretomes on the proteome of ovarian cancer cells
Exogenous signals from drug-stressed cancer cells promote acquisition of a more aggressive phenotype of neighboring tumor cells. Recently, we examined how cancer cell secretome changes in response to chemotherapy. Moreover, therapy-induced secretomes significantly increased resistance of cancer cell...
ORGANISM(S): Homo sapiens (Human) 
2024-05-29 | PXD027794 | Pride
Ovarian cancer Therapy-induced secretome 
GenomicsWidespread multi-targeted therapy resistance via drug-induced secretome fucosylation
Widespread multi-targeted therapy resistance via drug-induced secretome fucosylation
PRJNA672332 | ENA
ProteomicsWidespread multi-targeted therapy resistance via drug-induced secretome fucosylation
Cancer secretome is a reservoir for aberrant glycosylation. How therapies alter this post translational cancer hallmark and the consequences thereof remain elusive. Here we show that an elevated secretome fucosylation is a pan-cancer signature of both response and resistance to multiple targeted the...
ORGANISM(S): Homo sapiens (Human) 
2023-04-05 | PXD022240 | Pride
N-linked glycosylation Resistance Fucosylation Targeted therapy Secretome 
TranscriptomicsGene expression profiling in porcine chronic myocardial ischemia treated with intramyocardial injections of secretome
Closed-chest reperfused MI was induced in pigs by 90-min occlusion, followed by reperfusion of the mid LAD (day 0) and by cardiac MRI with late enhancement (LE) at day 3. At day 30 the animals received either porcine APOSEC (n=8) or placebo medium (n=8) in a randomized manner, injected into the bord...
ORGANISM(S): Sus scrofa 
2013-12-31 | E-GEOD-47397 | biostudies-arrayexpress
GenomicsGene expression profiling of MDA-MB-231 cells incubated with therapy induced senescence secretome
Gene expression profiling of MDA-MB-231 cells incubated with therapy induced senescence secretome
PRJNA993184 | ENA
UnknownMulti-targeted therapy resistance via drug-induced secretome fucosylation.
Not available
S-EPMC10089660 | biostudies-literature
TranscriptomicsWidespread multi-targeted therapy resistance via drug-induced secretome fucosylation
Cancer secretome is a reservoir for aberrant glycosylation. How therapies alter this post59 translational cancer hallmark and the consequences thereof remain elusive. Here we show that an elevated secretome fucosylation is a pan-cancer signature of both response and resistance to multiple targeted t...
ORGANISM(S): Homo sapiens 
2023-04-05 | GSE160205 | GEO
GenomicsEffect of therapy-induced secretomes on the transcriptome of ovarian cancer cells
Effect of therapy-induced secretomes on the transcriptome of ovarian cancer cells
PRJNA1010741 | ENA
GenomicsSecretome analysis during human induced pluripotent stem cell-derived cardiomyocyte differentiation
Secretome analysis during human induced pluripotent stem cell-derived cardiomyocyte differentiation
PRJNA1424899 | ENA
Sort   by:  
 Page size